Despite decades of progress, many of the most lethal cancers—such as pancreatic, ovarian, stomach, liver, and lung—are still detected too late. This session will explore how advances in multi-cancer early detection, novel liquid biopsy science, and consumer-driven access models are reshaping the landscape. Come hear how cross-sector partnerships and new approaches to screening can help close some of the most persistent gaps in cancer detection and outcomes.
